- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03932578
Intrathecal Atropine vs IV Metoclopramide for Nausea & Vomiting During CS
Intrathecal Atropine Versus Intravenous Metoclopramide for Prevention of Nausea and Vomiting During Caesarian Section Under Spinal Anesthesia
Study Overview
Status
Intervention / Treatment
Detailed Description
Patients After obtaining the approval of the Mansoura Faculty of Medicine Institutional Research Board (MFM-IRB) and registration with ClinicalTrials.gov, this prospective double blind randomized study will be conducted in the next 6 months on 100 pregnant women undergoing elective CS in obstetric surgery unit in Mansoura University Hospital, Mansoura, Egypt. A written informed consent will be taken from each patient selected to participate before inclusion in the study.
Inclusion criteria Patients with ASA physical status class I or II; indications for CS other than fetal or maternal pathology and surgery scheduled for within 4 days of physiological term will be included in this study.
Exclusion criteria Patients with any of the following criteria will be excluded from the study: 1) age < 20 or > 35 years; 2) height < 150 or > 180 cm; 2) body mass index (BMI) >35 kg/m2; 4) active labor or emergency CS; 5) emesis gravidarum; 6) multifetal pregnancy; 7) fetal distress; 8) associated medical problem with pregnancy (as hypertension, diabetes mellitus, hepatic impairment or renal impairment);9) obstetric problem (as placenta previa or placental abruption); 10) contraindication for central neuraxial block; 11) history of adverse reaction to any study medication; 12) history of antiemetic drug use; or 13) refusal to undergo regional anesthesia.
Methods All patients participating in the study will be randomly divided into two groups; atropine group and metoclopramide group. The randomization will be simple and balanced (1:1) and will be carried out by a nurse through sealed, unlabeled, opaque envelopes containing computer-generated random numbers. The participants, caregivers and investigators will be blinded to group assignment. Patients in the atropine group will receive IV study solution which is 2 ml saline 0.9% as a placebo + intrathecal study solution which is a premised solution of 2.5 ml of 0.5% hyperbaric bupivacaine, 25 μg fentanyl and 100 μg of a 1 mg/ml preservative-free atropine sulfate solution. Patients in the metoclopramide group will receive IV study solution which is metoclopramide 10 mg in 2 ml + intrathecal study solution which is a premised solution of 2.5 ml of 0.5% hyperbaric bupivacaine, 25 μg fentanyl and 100 μg of preservative-free saline 0.9% as a placebo.
All participants will be instructed to stop oral intake 8 hours before surgery, but they will be allowed to drink moderate amounts of water and juices until 6 hours before surgery. Anesthesia protocol will be standardized in all patients. On arrival of the patient to operative theatre, intravenous (IV) cannula will be inserted and IV infusion of Ringer's acetate (8 ml/kg) will be given over about 20 minutes as a fluid preload before anesthesia. Patients will receive the IV study solution (according to their allocation) 15 minutes before start of anesthesia procedures. The spinal anesthesia will be performed in sitting position under strict aseptic condition. The anesthesia will be given at the level of L2-L3 or L3-L4 with a 25-gauge whit acre needle. Injections will be made using three separate syringes. Patients will be placed in a supine position immediately after the end of injections. A left lateral posture will be applied to all patients.
Sensory block will be assessed every 2 minute after intrathecal injection by using analgesia to pinprick in midclavicular line until achieving a stable level of sensory block. Surgery will be permitted after achieving T6 sensory block level. If the sensory level will not reach this level this case will be excluded from the study, and general anesthesia will be then given. Motor block will be assessed by using modified Bromage score (BS) in which, BS0 means no motor block; BS1 means inability to raise extended legs; BS2 means inability to flex knees; BS3 means inability to flex ankle joints. Complete motor block will be defined as BS3.
Heart rate, noninvasive arterial blood pressure and peripheral oxygen saturation (SpO2) measurements will be assessed in both groups preoperatively, during shifting and every 10 minutes intraoperatively. Hypotension will be defined as systolic blood pressure < 100 mmHg or > 30% decrease in baseline values. Bradycardia will be defined as heart rate < 60 bpm or a 20% drop in heart rate. Hypotension will be treated initially by bolus IV infusion of crystalloids (300 ml) then IV ephedrine 5 mg will be administered as needed. Bradycardia will be treated with fluids, positioning and ephedrine (up to 25 mg).If bradycardia does not resolve within seconds of treatment, IV atropine sulphate 0.5 mg will be given every 30 seconds until resolution. Patients who will receive IV atropine in addition to the study dose will be excluded from the study. After delivery, bradycardia will be only treated if hypotension is also present, or when the heart rate is <60 bpm.
Outcome measures The main outcome measure will be occurrence of IONV or PONV. Any IONV or PONV rating > 3 or spontaneous reporting of IONV or PONV by patients during scheduled interviews, as well as any clinical manifestations (retching or vomiting) and any requests for antiemetic medication will be considered as episodes of NV. Other outcome measures will be pain at rest, hypotension, bradycardia, shivering, pruritus, unexplained anxiety, xerostomia, photophobia, and the time of the first request for antiemetic drugs and analgesics and the number of requests until 12 h postoperatively.
Statistical analysis The statistical analysis will be performed using the IBM® SPSS® Statistics, version 20.0 for Windows. Continuous variables will be expressed as mean ± standard deviation (SD) and categorical variables will be expressed as frequencies and percentages. The normality distribution of continuous variables will be tested with the Kolmogorov-Smirnov and Shapiro-Wilk tests. Differences among continuous variables with normal distribution will be compared with the t-test while for continuous variables without normal distribution, non-parametric tests will be used and differences will be compared with the Mann-Whitney U-test. Differences between percentages will be compared with the Fisher's exact test. P values ≤ 0.05 will be considered statistically significant.
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
Dakahlia
-
Mansoura, Dakahlia, Egypt, 35111
- Mansoura University Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients with ASA physical status class I or II; indications for CS other than fetal or maternal pathology and surgery scheduled for within 4 days of physiological term will be included in this study
Exclusion Criteria:
- Height < 150 or > 180 cm
- Body mass index (BMI) >35 kg/m2
- Active labor or emergency CS
- Emesis gravidarum
- Multifetal pregnancy
- Fetal distress
- Associated medical problem with pregnancy (as hypertension, diabetes mellitus, hepatic impairment or renal impairment)
- Obstetric problem (as placenta previa or placental abruption)
- Contraindication for central neuraxial block
- History of adverse reaction to any study medication
- History of antiemetic drug use
- Refusal to undergo regional anesthesia
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Atropine group
Patients will receive IV study solution which is 2 ml saline 0.9% as a placebo + intrathecal study solution which is a premised solution of 2.5 ml of 0.5% hyperbaric bupivacaine, 25 μg fentanyl and 100 μg of a 1 mg/ml preservative-free atropine sulfate solution
|
Patients will receive intrathecal 100 μg of a 1 mg/ml preservative-free atropine sulfate solution
|
Active Comparator: Metoclopramide group
Patients in will receive IV study solution which is metoclopramide 10 mg in 2 ml + intrathecal study solution which is a premised solution of 2.5 ml of 0.5% hyperbaric bupivacaine, 25 μg fentanyl and 100 μg of preservative-free saline 0.9% as a placebo
|
Patients will receive IV metoclopramide 10 mg in 2 ml
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Intraoperative nausea and vomiting (IONV)
Time Frame: During CS
|
Spontaneous reporting of IONV by patients, as well as any clinical manifestations (retching or vomiting) and any requests for antiemetic medication will be considered as episodes of NV
|
During CS
|
Postoperative nausea and vomiting (PONV)
Time Frame: 12 hours after CS
|
Spontaneous reporting of PONV by patients during scheduled interviews, as well as any clinical manifestations (retching or vomiting) and any requests for antiemetic medication will be considered as episodes of NV
|
12 hours after CS
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Time of requiring antiemetics
Time Frame: Until 12 hours postoperatively
|
The time of the first request for antiemetic drugs
|
Until 12 hours postoperatively
|
Number of requiring antiemetics
Time Frame: Until 12 hours postoperatively
|
The number of requests for antiemetic drugs
|
Until 12 hours postoperatively
|
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: Mohamed S Abdelhafez, MD, Mansoura University
- Principal Investigator: Tamer Elmetwally, MD, Mansoura University
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Signs and Symptoms, Digestive
- Nausea
- Vomiting
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Anti-Arrhythmia Agents
- Parasympatholytics
- Autonomic Agents
- Peripheral Nervous System Agents
- Muscarinic Antagonists
- Cholinergic Antagonists
- Cholinergic Agents
- Antiemetics
- Gastrointestinal Agents
- Dopamine Agents
- Dopamine D2 Receptor Antagonists
- Dopamine Antagonists
- Adjuvants, Anesthesia
- Bronchodilator Agents
- Anti-Asthmatic Agents
- Respiratory System Agents
- Mydriatics
- Atropine
- Metoclopramide
Other Study ID Numbers
- MSA10
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- Study Protocol
- Statistical Analysis Plan (SAP)
- Informed Consent Form (ICF)
- Clinical Study Report (CSR)
- Analytic Code
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Nausea
-
University of North Carolina, Chapel HillNational Institute of Dental and Craniofacial Research (NIDCR)CompletedPost-operative Nausea | Post-operative Vomiting | Nausea PersistentUnited States
-
Cukurova UniversityTarsus UniversityRecruitingNausea, Postoperative | Vomiting, Postoperative | APFEL RİSK SCORETurkey
-
MonoSol RxCompletedNausea With Vomiting Chemotherapy-Induced | Nausea and Vomiting, PostoperativeIndia
-
GlaxoSmithKlineCompletedPostoperative Nausea and Vomiting | Nausea and Vomiting, PostoperativeUnited States, Spain, Philippines, Israel, Hong Kong, Thailand, United Kingdom, Hungary, Slovenia, Norway, Denmark
-
Hoffmann-La RocheCompletedPost-Operative Nausea and VomitingUnited States
-
Cairo UniversityUnknownPost Operative Nausea and VomitingEgypt
-
Yonsei UniversityCompletedPost Operative Nausea and VomitingKorea, Republic of
-
Lancaster General HospitalCompletedBariatric Surgery Candidate | Nausea, PostoperativeUnited States
-
AccentureCompletedPost-Operative Nausea and Vomiting (PONV)Australia
-
Blokhin's Russian Cancer Research CenterRUSSCO/RakFondUnknownChemotherapy-induced Nausea and Vomiting | Nausea | Vomiting | Emesis | Nausea Post ChemotherapyRussian Federation
Clinical Trials on Atropine sulfate
-
Zhaoke (Guangzhou) Ophthalmology Pharmaceutical...Active, not recruiting
-
LitePharmTech Co., Ltd.RecruitingChildren | MyopiaKorea, Republic of
-
TakedaTerminatedRheumatoid ArthritisUnited States, Argentina, Canada, Czech Republic, Germany, Hungary, Italy, Mexico, Poland, Spain, United Kingdom
-
Zhaoke (Hong Kong) Ophthalmology Pharmaceutical...Recruiting
-
Shanghai Eye Disease Prevention and Treatment CenterShanghai General Hospital, Shanghai Jiao Tong University School of MedicineUnknown
-
University of UtahActive, not recruiting
-
Shanghai Eye Disease Prevention and Treatment CenterShanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University and other collaboratorsRecruiting
-
Washington University School of MedicineAmerican Diabetes AssociationCompletedPre-diabetesUnited States
-
Zhaoke (Guangzhou) Ophthalmology Pharmaceutical...Active, not recruiting
-
Jeffrey J. Walline, OD PhDCompleted